Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Sep 3;3(9):e3130.
doi: 10.1371/journal.pone.0003130.

Role of N-terminal amino acids in the potency of anthrax lethal factor

Affiliations

Role of N-terminal amino acids in the potency of anthrax lethal factor

Pradeep K Gupta et al. PLoS One. .

Abstract

Anthrax lethal factor (LF) is a Zn(+2)-dependent metalloprotease that cleaves several MAPK kinases and is responsible for the lethality of anthrax lethal toxin (LT). We observed that a recombinant LF (LF-HMA) which differs from wild type LF (LF-A) by the addition of two residues (His-Met) to the native Ala (A) terminus as a result of cloning manipulations has 3-fold lower potency toward cultured cells and experimental animals. We hypothesized that the "N-end rule", which relates the half-life of proteins in cells to the identity of their N-terminal residue, might be operative in the case of LF, so that the N-terminal residue of LF would determine the cytosolic stability and thereby the potency of LF. Mutational studies that replaced the native N-terminal residue of LF with known N-end rule stabilizing or destabilizing residues confirmed that the N-terminal residue plays a significant role in determining the potency of LT for cultured cells and experimental animals. The fact that a commercially-available LF preparation (LF-HMA) that is widely used in basic research studies and for evaluation of vaccines and therapeutics is 3-fold less potent than native LF (LF-A) should be considered when comparing published studies and in the design of future experiments.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The senior author (SHL) receives royalties resulting from the sale of certain anthrax toxin proteins by List Laboratories that are produced under license from NIH.

Figures

Figure 1
Figure 1. Schematic representation of various LF proteins.
All proteins (except LF-A/St which is wild type LF produced from Sterne strain) were generated as secreted proteins from B. anthracis BH450. All proteins contained a signal peptide that is cleaved by signal peptidases during secretion. Constructs with a factor Xa recognition sequence alone or preceded by the Myc epitope tag are labeled “/X” or “/MyX”, respectively. These proteins were produced as precursor proteins followed by cleavage with factor Xa protease to generate the indicated N-termini. Residue (Z) circled in red indicates the residue mutated for each protein, i.e., Z = A, H, M, R, F, G in different mutated LF constructs.
Figure 2
Figure 2. Cytotoxicity of LF proteins to RAW264.7 cells.
RAW264.7 cells were incubated with various concentrations of LF-HMA, LF-A, and LF-A/X proteins (A) or LF proteins with mutated N-termini (B) and a fixed concentration of PA (250 ng/ml). Cell viability was assessed at 3 h. Percent viability was calculated relative to cells treated with medium (no toxin).
Figure 3
Figure 3. Toxicity of LF proteins to mice.
(A) LF-HMA and LF-A/St (100 µg) were injected in Balb/cJ mice in combination with 100 µg PA via the IP route and survival was monitored for 120 h. Each group contained n = 5 mice. (B) LF proteins (100 µg) were injected in Balb/cJ mice in combination with 100 µg PA via the IP route and survival was monitored for 120 h. Mouse numbers used in this experiment were as follows: LF-HMA (n = 9), LF-A (n = 9), LF-A/X (n = 5), LF-G/MyX (n = 3) and all other groups n = 4. (*) The animals in LF-G/MyX and LF-R/MyX groups exhibited substantial malaise starting at 24 h and throughout the experiment and were euthanized at 128 h to prevent suffering in accordance with approved animal protocols. (C) LF preparations (40 µg) were injected in Balb/cJ mice in combination with 40 µg PA via the IP route and survival was monitored for 120 h. Mouse numbers used in this experiment were as follows: LF-HMA (n = 14), LF-A (n = 9), LF-A/X (n = 5) and all other groups n = 4. (**) The surviving animals in these groups did not display any signs of malaise over the last 48 h of the experiment.
Figure 4
Figure 4. Evaluation of the apparent binding affinities of LF-HMA and LF-A for PA using Schild Plot analyses.
CHO WTP4 cells were incubated with various concentrations of FP59 plus a set concentration of PA (12 nM) and different concentrations of LF-HMA (A) or LF-A (B) for 3 h. After toxin removal, cells were incubated with the toxin-free medium containing 10 mM NH4Cl for 48 h before assessment of cell viability. Schild Plot analyses were performed as described in “Methods” to assess K ds of each LF protein for PA. Inserts shown in panels A and B are non-linear regression curves obtained from these analyses using GraphPad Prism.

References

    1. Mourez M. Anthrax toxins. Rev Physiol Biochem Pharmacol. 2004;152:135–164. - PubMed
    1. Leppla SH. Bacillus anthracis toxins. In: Alouf JE, Popoff MR, editors. The Comprehensive Sourcebook of Bacterial Protein Toxins. Burlington, MA: Academic Press; 2006. pp. 323–347.
    1. Leppla SH. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proc Natl Acad Sci U S A. 1982;79:3162–3166. - PMC - PubMed
    1. Duesbery NS, Webb CP, Leppla SH, Gordon VM, Klimpel KR, et al. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science. 1998;280:734–737. - PubMed
    1. Pellizzari R, Guidi-Rontani C, Vitale G, Mock M, Montecucco C. Lethal factor of Bacillus anthracis cleaves the N-terminus of MAPKKs: analysis of the intracellular consequences in macrophages. Int J Med Microbiol. 2000;290:421–427. - PubMed

Publication types